Abstract
This is the first article in a four-part series on new radiopharmaceuticals. Upon completion of this article, the nuclear medicine technologist will be able to: (1) understand the important aspects of this technetium-99m-labeled myocardial perfusion agent, and (2) identify important imaging parameters.